Skip to main content
main-content
Erschienen in: Gastro-News 2/2022

20.04.2022 | Chronisch-entzündliche Darmerkrankungen | Aktuell

UEGW 2021 virtual - Teil 2

Neues zu Kolon und CED vom europäischen Gastroenterologie-Kongress

verfasst von: Prof. Dr. med. Dr. rer. biol. hum. Manfred Gross, Priv.-Doz. Dr. med. Birgit Terjung

Erschienen in: Gastro-News | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Auszug

Bei der europäischen UEGW (United European Gastroenterology Week), die erneut im digitalen Format stattfand, stellte die COVID-19-Pandemie neben "klassischen" Themen wieder ein zentrales Thema in zahlreichen Abstracts dar. Die wichtigsten Forschungsergebnisse der UEGW 2021 zum Thema Kolon und chronisch entzündlicher Darmerkrankungen sind in diesem Artikel zusammengefasst.
Literatur
1.
Zurück zum Zitat Magro F, COVID-19: Lessons learned, UEG 2021, invited oral presentation Magro F, COVID-19: Lessons learned, UEG 2021, invited oral presentation
2.
Zurück zum Zitat Domper Arnal MJ, Alfaro E, Navarro M et al. Impact of the COVID-19 pandemic in the diagnosis and characteristics of colorectal cancer patients. United European Gastroenterol J. 2021;9:887 P1086 Domper Arnal MJ, Alfaro E, Navarro M et al. Impact of the COVID-19 pandemic in the diagnosis and characteristics of colorectal cancer patients. United European Gastroenterol J. 2021;9:887 P1086
3.
Zurück zum Zitat Ricciardiello L, Invited Presentation 335, UEGW 2021 Ricciardiello L, Invited Presentation 335, UEGW 2021
4.
Zurück zum Zitat Rottoli M, G. Pellino G, Spinelli A et al. The impact of COVID-19 on the oncologic outcomes of 3236 patients undergoing colorectal cancer surgery in northern Italy in 2019 und 2020 (COVID-CRC): Results of a multicentric comparative cohort study. United European Gastroenterol J. 2021;9:242 MP123 Rottoli M, G. Pellino G, Spinelli A et al. The impact of COVID-19 on the oncologic outcomes of 3236 patients undergoing colorectal cancer surgery in northern Italy in 2019 und 2020 (COVID-CRC): Results of a multicentric comparative cohort study. United European Gastroenterol J. 2021;9:242 MP123
5.
Zurück zum Zitat Saraiva S, Rosa I, Marques I et al. The impact of COVID-19 in colorectal cancer care. United European Gastroenterol J. 2021;9:615 P0574 Saraiva S, Rosa I, Marques I et al. The impact of COVID-19 in colorectal cancer care. United European Gastroenterol J. 2021;9:615 P0574
6.
Zurück zum Zitat Damm M, Garbe J, Stephan Eisenmann S et al. Challenges of the COVID-19 pandemic in gastrointestinal endoscopy: expectations and implementation of recommendations. Z Gastroenterol. 2020;58:1074-80 Damm M, Garbe J, Stephan Eisenmann S et al. Challenges of the COVID-19 pandemic in gastrointestinal endoscopy: expectations and implementation of recommendations. Z Gastroenterol. 2020;58:1074-80
7.
Zurück zum Zitat Krüger J, Müller J, Groß R et al. SARS-CoV-2 infects and replicates in cells of the human pancreas. United European Gastroenterol J. 2021;9:891P1092 Krüger J, Müller J, Groß R et al. SARS-CoV-2 infects and replicates in cells of the human pancreas. United European Gastroenterol J. 2021;9:891P1092
8.
Zurück zum Zitat Sierra O, Julian B, Casas D et al. COVID-19 and acute pancreatitis: more serious and lethal. United European Gastroenterol J. 2021;9:733 P0799 Sierra O, Julian B, Casas D et al. COVID-19 and acute pancreatitis: more serious and lethal. United European Gastroenterol J. 2021;9:733 P0799
9.
Zurück zum Zitat Sinonquel P, Huang I-H, Camps C et al. Impact on aerosol generation of a mouthpiece designed to reduce droplet spread of COVID-19 during upper gastrointestinal endoscopy, a single center randomized controlled trial. United European Gastroenterol J. 2021;9:782 P0888 Sinonquel P, Huang I-H, Camps C et al. Impact on aerosol generation of a mouthpiece designed to reduce droplet spread of COVID-19 during upper gastrointestinal endoscopy, a single center randomized controlled trial. United European Gastroenterol J. 2021;9:782 P0888
10.
Zurück zum Zitat Sunakawa H, Yoda Y, Takashima K et al. A prospective observational study on the evaluation of the risk of transmission due to droplets and aerosols during esophagogastroduodenoscopy and the usefulness of extraoral suction devices. United European Gastroenterol J. 2021;9:887 P1085 Sunakawa H, Yoda Y, Takashima K et al. A prospective observational study on the evaluation of the risk of transmission due to droplets and aerosols during esophagogastroduodenoscopy and the usefulness of extraoral suction devices. United European Gastroenterol J. 2021;9:887 P1085
11.
Zurück zum Zitat Sultan S, Siddique SM, Singh S et al. AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update Gastroenterology. 2021 Sep;161(3):1011-29.e11 Sultan S, Siddique SM, Singh S et al. AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update Gastroenterology. 2021 Sep;161(3):1011-29.e11
12.
Zurück zum Zitat Schuppan D, Mäki M, Knut EA et al. A randomized trial fo transglutamase 2 inhibitor für celiac disease. N Engl J Med. 2021;385:35-45 Schuppan D, Mäki M, Knut EA et al. A randomized trial fo transglutamase 2 inhibitor für celiac disease. N Engl J Med. 2021;385:35-45
13.
Zurück zum Zitat Schuppan D, Mäki M, Lundin KE et al. Oral TG2 inhibitor effective and well tolerated in celiac disease. United European Gastroenterol J 2021;9(S8): LB06 Schuppan D, Mäki M, Lundin KE et al. Oral TG2 inhibitor effective and well tolerated in celiac disease. United European Gastroenterol J 2021;9(S8): LB06
14.
Zurück zum Zitat Guagnozzi D, Gonzalez-Castro AM, Fernandez-Banares F et al. Structural alterations of colonic microvilli in microscopic colitis and restoration by oral budesonide. United European Gastroenterol J. 2021; 9(S8): P0250 Guagnozzi D, Gonzalez-Castro AM, Fernandez-Banares F et al. Structural alterations of colonic microvilli in microscopic colitis and restoration by oral budesonide. United European Gastroenterol J. 2021; 9(S8): P0250
15.
Zurück zum Zitat Miehlke S, Guagnozzi D, Zabana Y et al. European Guidelines on microscopic colitis. United European Gastroenterol J. 2021;9:13-37 Miehlke S, Guagnozzi D, Zabana Y et al. European Guidelines on microscopic colitis. United European Gastroenterol J. 2021;9:13-37
16.
Zurück zum Zitat Antolin-Fontes B , Zhuleku E, Borsi A et al. Crohn's disease real world therapy in prevalent CD-patients in Germany - there is still a great burden of disease. United European Gastroenterol J. 2021; 9(S8): MP003 Antolin-Fontes B , Zhuleku E, Borsi A et al. Crohn's disease real world therapy in prevalent CD-patients in Germany - there is still a great burden of disease. United European Gastroenterol J. 2021; 9(S8): MP003
17.
Zurück zum Zitat Sturm A, Atreya R, Bettenworth D et al. Aktualisierte S3-Leitlinie "Diagnostik und Therapie des Morbus Crohn" der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). August 2021 - AWMF Nr. 021-004 Sturm A, Atreya R, Bettenworth D et al. Aktualisierte S3-Leitlinie "Diagnostik und Therapie des Morbus Crohn" der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). August 2021 - AWMF Nr. 021-004
18.
Zurück zum Zitat Kucharzik T, Dignass A, Atreya R et al. Aktualisierte S3-Leitlinie Colitis ulcerosa - Living Guideline. August 2020 - AWMF 021-009. Z Gastroenterol. 2020;58:241-326 Kucharzik T, Dignass A, Atreya R et al. Aktualisierte S3-Leitlinie Colitis ulcerosa - Living Guideline. August 2020 - AWMF 021-009. Z Gastroenterol. 2020;58:241-326
19.
Zurück zum Zitat Turner D, Ricciuto A, Lewis A, [ …..], Dignass A, [...] STRIDE II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE). Initiative of the International Organization for the Study of IBD (IOBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-83 Turner D, Ricciuto A, Lewis A, [ …..], Dignass A, [...] STRIDE II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE). Initiative of the International Organization for the Study of IBD (IOBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-83
20.
Zurück zum Zitat Schreiber S, D'Haens G, Cummings F et al. Switching from intravenous to subkutaneous infliximab in patients with active inflammatory bowel disesase: post-hoc analysis of pre/post switch outcomes from a multicentre, randomised controlled pivotal trial. United European Gastroenterol J. 2021;9(S8):P0472 Schreiber S, D'Haens G, Cummings F et al. Switching from intravenous to subkutaneous infliximab in patients with active inflammatory bowel disesase: post-hoc analysis of pre/post switch outcomes from a multicentre, randomised controlled pivotal trial. United European Gastroenterol J. 2021;9(S8):P0472
21.
Zurück zum Zitat Smith P, Storey D, Gregg B et al. Efficacy and safety of elective switching of inflammatory bowel disease patients from intravenous to subkutaneous infliximab: a multi-centre cohort study. United European Gastroenterol J. 2021;9(S8):OP155 Smith P, Storey D, Gregg B et al. Efficacy and safety of elective switching of inflammatory bowel disease patients from intravenous to subkutaneous infliximab: a multi-centre cohort study. United European Gastroenterol J. 2021;9(S8):OP155
22.
Zurück zum Zitat D'Haens G, Reinisch W, Schreiber S et al. Comparison of combination subkutaneous infliximab and immunomodulator versus subkutaneous infliximab monotherapy: post-hoc analysis of a randomised clinical trial. United European Gastroenterol J. 2021;9(S8):P0467 D'Haens G, Reinisch W, Schreiber S et al. Comparison of combination subkutaneous infliximab and immunomodulator versus subkutaneous infliximab monotherapy: post-hoc analysis of a randomised clinical trial. United European Gastroenterol J. 2021;9(S8):P0467
23.
Zurück zum Zitat Danese S, Sands B, Irving PM et al. The pharmacokinetics and immunogenicity of ustekinumab and adalimumab in patients with moderate-to-severe Crohn's disease: results from the SEAVUE study. United European Gastroenterol J. 2021;9(S8):LB15 Danese S, Sands B, Irving PM et al. The pharmacokinetics and immunogenicity of ustekinumab and adalimumab in patients with moderate-to-severe Crohn's disease: results from the SEAVUE study. United European Gastroenterol J. 2021;9(S8):LB15
24.
Zurück zum Zitat Allez M, Lewis JD, Irving PM et al. Health-related quality of life with ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderate-to-severe Crohn's disease: PROMIS-29 in the SEAVUE Study. United European Gastroenterol J. 2021; 9(S8):OP122 Allez M, Lewis JD, Irving PM et al. Health-related quality of life with ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderate-to-severe Crohn's disease: PROMIS-29 in the SEAVUE Study. United European Gastroenterol J. 2021; 9(S8):OP122
25.
Zurück zum Zitat Stallmach A, Sturm A, Blumenstein I et al. Addendum zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch entzündlichen Darmerkrankungen in der COVID-19-Pandemie - offene Fragen und Antworten. Z Gastroenterol. 2020;58:672-92 Stallmach A, Sturm A, Blumenstein I et al. Addendum zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch entzündlichen Darmerkrankungen in der COVID-19-Pandemie - offene Fragen und Antworten. Z Gastroenterol. 2020;58:672-92
26.
Zurück zum Zitat Magro F, Rahier JF, Abreu C et al. Inflammatory bowel disease management during the COVID-19 outbreak: the ten do's and don'ts from the ECCO-COVID Taskforce. JCC. 2020;798-806 Magro F, Rahier JF, Abreu C et al. Inflammatory bowel disease management during the COVID-19 outbreak: the ten do's and don'ts from the ECCO-COVID Taskforce. JCC. 2020;798-806
27.
Zurück zum Zitat Siegel CA, Melmed GY, McGovern DP et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021;70(4):635-40 Siegel CA, Melmed GY, McGovern DP et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021;70(4):635-40
28.
Zurück zum Zitat Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A et al. Decreased immunse response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti TNA-a: a prospective, controlled, multi-center israeli study. United European Gastroenterol J 2021;9(S8):OP020 Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A et al. Decreased immunse response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti TNA-a: a prospective, controlled, multi-center israeli study. United European Gastroenterol J 2021;9(S8):OP020
29.
Zurück zum Zitat Kennedy NA, Lin S, Goodhand JR et al. Infliximab is associated with attenuated immunogenicitiy to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021;70(10):1884-93 Kennedy NA, Lin S, Goodhand JR et al. Infliximab is associated with attenuated immunogenicitiy to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021;70(10):1884-93
Metadaten
Titel
UEGW 2021 virtual - Teil 2
Neues zu Kolon und CED vom europäischen Gastroenterologie-Kongress
verfasst von
Prof. Dr. med. Dr. rer. biol. hum. Manfred Gross
Priv.-Doz. Dr. med. Birgit Terjung
Publikationsdatum
20.04.2022
Verlag
Springer Medizin
Erschienen in
Gastro-News / Ausgabe 2/2022
Print ISSN: 1869-1005
Elektronische ISSN: 2520-8667
DOI
https://doi.org/10.1007/s15036-022-2485-3

Weitere Artikel der Ausgabe 2/2022

Gastro-News 2/2022 Zur Ausgabe

Passend zum Thema

ANZEIGE
CU – Neuer Wirkstoff

Neue Therapieoption bei Colitis ulcerosa

Für die Therapie der mittelschweren bis schweren aktiven Colitis ulcerosa bei Erwachsenen steht ein neues Therapeutikum mit überzeugenden Ergebnissen bei schnellem Ansprechen, anhaltender Remission und Mukosaheilung zur Verfügung. [1,2,a-c]

Corona-Update

Die aktuelle Entwicklung im Überblick: Nachrichten, Webinare, Übersichtsarbeiten.